July 18, 2011
Cord Blood America CEO Matthew Schissler Interviewed on International Successes
LAS VEGAS, July 18, 2011 /PRNewswire/ -- Cord Blood America, Inc. (http://www.cordblood-america.com) (OTC Bulletin Board: CBAI), the umbilical cord blood stem cell preservation company focused on bringing the life saving potential of stem cells to families nationwide and internationally, said today that co-founder and CEO Matthew Schissler was interviewed by analyst Francis Gaskins about the Company's international successes.
The entire interview is available at: http://gaskinsco.com/cbai-7-15-11.mp3Mr. Schissler said in the interview that as more research shows the usefulness of stem cells in therapies combating numerous diseases, more of the "raw material," the stored stem cells, will be needed. He said that is one reason Cord Blood America is establishing an "international brand," with hubs in Argentina, Europe and China to become a worldwide leader in providing needed stem cells.
Cord Blood America's CEO said BioCells, Inc., its Argentina-headquartered stem cell company, has recently opened eight franchises in the same number of cities in that country, besides opening an office in Miami for Latin Americans in the U.S. Sales have been strong in South America, Mr. Schissler said. Stellacure GmbH, the Company's stem cell firm headquartered in Germany, is part of a broadbased strategy to be invested in small stem cell companies throughout the Continent, including in Spain and Italy, Cord Blood America's CEO said.
In the interview, Mr. Schissler also comments on the stem cell collection facility in China, in which Cord Blood America is a minority partner.
About Cord Blood America
Cord Blood America is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc., visit our website at http://www.corcell.com/. For investor information, visit http://www.cordblood-america.com/.
E & E Communications
Safe Harbor: This press release contains forward-looking statements. Forward-looking statements, which involve assumptions and describe our future plans, strategies and expectations, are generally identifiable by use of the words "may," "will," "should," "expect," "anticipate," "estimate," "believe," "intend" or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned that such forward looking statements should not be construed as a guarantee or assurance of future performance or results. Actual events or results may differ materially from those discussed in forward-looking statements as a result of various factors. In light of these risks and uncertainties, there can be no assurance that the forward-looking statements contained herein will in fact occur. These forward-looking statements are based on current expectations, and the Company assumes no obligation to update this information. Readers are urged to carefully review and consider the various disclosures made by the Company in its Form 10-K and in the Company's other reports filed with the Securities and Exchange Commission that discuss certain of the risks and factors that may affect the Company and its business.
SOURCE Cord Blood America, Inc.